Osimertinib associated with longer overall survival versus comparator EGFR-TKIs
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in ...
Tag: osimertinib
Osimertinib improves progression-free survival in EGFR-mutated non-small-cell lung cancer: The FLAURA trial
1. Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine ...
2 Minute Medicine Rewind February 20, 2017
Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer First line treatment for patients with advanced, non-small cell lung cancers that ...
